Head-to-head · WeighScore
Bliv vs Eve
The verdict
Too close to call — both grade 66.3/100 (C).
Bliv and Eve land on the same WeighScore, so neither clears the other on our six graded dimensions. Bliv sits one line higher on the board (#187 vs #189) on the underlying tiebreak, but it's a genuine coin-flip — pick on the factors and prices that matter most to you below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Bliv | Eve |
|---|---|---|
| WeighScore | 66.3/100 | 66.3/100 |
| Grade | C | C |
| Scorecard rank | #187 | #189 |
| Semaglutide | $116/mo (as low as, varies by plan and eligibility, compounded) | $195/mo (compounded) |
| Tirzepatide | $199/mo (as low as, varies by plan and eligibility, compounded) | $195/mo (compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Yes |
Graded #187 · C
Strengths
- Both semaglutide and tirzepatide available
- Compounded GLP-1 access
Where it loses points
- The advertised rates are 'as low as' figures footnoted 'based on plan structure and eligibility', and the plan selector sits behind the medical intake — the rate you are offered is not knowable before you hand over a medical history
- A $24.99 provider consultation fee is charged on top, and the refund policy deducts $200 for 'clinical coordination and account setup'
- The homepage advertises 'no long-term commitments or cancellation fees' while the terms require the membership fee to be paid 'in a single sum', call it non-refundable and refer to a 'Membership Term'
- The only figure smaller than the advertised rate is a $29 CareCredit/Klarna instalment, which is a financing payment rather than the price of a month of medication
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Graded #189 · C
Strengths
- Genuinely women's-health-focused — fills a real gap among gender-neutral GLP-1 competitors
- Both compounded and brand-name FDA-approved options (Wegovy/Ozempic/Mounjaro) on one platform — rare
- LegitScript Certified with a verifiable ID
- Publishes the FDA compounded-medication disclaimer
- Oral sublingual semaglutide offered alongside injectable
Where it loses points
- Full states-served list not disclosed publicly
- 503A pharmacy partner not named, and 503A vs 503B status not specified
- Named medical director / clinical leadership not disclosed
- Corporate legal entity not disclosed
- Governing law / arbitration venue not stated
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.